Adherence to CPAP Treatment and the Risk of Recurrent Cardiovascular Events: A Meta-Analysis
Year: 2023
Type: review
Study designs: Systematic Review, Meta-Analysis
Abstract: Importance: The effect of continuous positive airway pressure (CPAP) on secondary cardiovascular disease prevention is highly debated. Objective: To assess the effect of CPAP treatment for obstructive sleep apnea (OSA) on the risk of adverse cardiovascular events in randomized clinical trials. Data Sources: PubMed (MEDLINE), EMBASE, Current Controlled Trials: metaRegister of Controlled Trials, ISRCTN Registry, European Union clinical trials database, CENTRAL (Cochrane Central Register of Controlled Trials), and ClinicalTrials.gov databases were systematically searched through June 22, 2023. Study Selection: For qualitative and individual participant data (IPD) meta-analysis, randomized clinical trials addressing the therapeutic effect of CPAP on cardiovascular outcomes and mortality in adults with cardiovascular disease and OSA were included. Data Extraction and Synthesis: Two reviewers independently screened records, evaluated potentially eligible primary studies in full text, extracted data, and cross-checked errors. IPD were requested from authors of the selected studies (SAVE [NCT00738179], ISAACC [NCT01335087], and RICCADSA [NCT00519597]). Main Outcomes and Measures: One-stage and 2-stage IPD meta-analyses were completed to estimate the effect of CPAP treatment on risk of recurrent major adverse cardiac and cerebrovascular events (MACCEs) using mixed-effect Cox regression models. Additionally, an on-treatment analysis with marginal structural Cox models using inverse probability of treatment weighting was fitted to assess the effect of good adherence to CPAP (≥4 hours per day). Results: A total of 4186 individual participants were evaluated (82.1% men; mean [SD] body mass index, 28.9 [4.5]; mean [SD] age, 61.2 [8.7] years; mean [SD] apnea-hypopnea index, 31.2 [17] events per hour; 71% with hypertension; 50.1% receiving CPAP [mean {SD} adherence, 3.1 {2.4} hours per day]; 49.9% not receiving CPAP [usual care], mean [SD] follow-up, 3.25 [1.8] years). The main outcome was defined as the first MACCE, which was similar for the CPAP and no CPAP groups (hazard ratio, 1.01 [95% CI, 0.87-1.17]). However, an on-treatment analysis by marginal structural model revealed a reduced risk of MACCEs associated with good adherence to CPAP (hazard ratio, 0.69 [95% CI, 0.52-0.92]). Conclusions and Relevance: Adherence to CPAP was associated with a reduced MACCE recurrence risk, suggesting that treatment adherence is a key factor in secondary cardiovascular prevention in patients with OSA.
Source: JAMA
Authors: Manuel Sánchez-de-la-Torre, Esther Gracia-Lavedan, Ivan D. Benitez, Alicia Sánchez-de-la-Torre, Anna Moncusí-Moix, Gerard Torres, Kelly Loffler, Richard Woodman, Robert Adams, Gonzalo Labarca, Jorge Dreyse, Christine Eulenburg, Erik Thunström, Helena Glantz, Yüksel Peker, Craig Anderson, Doug McEvoy, Ferran Barbé
Institutions: Universitat de Lleida, Hospital Universitari Arnau de Vilanova, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Investigación Biomédica de Lleida, Flinders University, Brigham and Women's Hospital, Harvard University, University of Concepción, Clínica Las Condes, University Medical Center Hamburg-Eppendorf, University of Gothenburg, Koç University, University of Pittsburgh, Lund University, UNSW Sydney, The George Institute for Global Health
Language: English
Subfield: Physiology (medical)
Field: Medicine
Domain: Health Sciences
Keywords: continuous positive airway pressure, CPAP adherence, obstructive sleep apnea, major adverse cardiovascular events, cardiovascular disease prevention, secondary prevention, cardiovascular mortality, cerebrovascular events, marginal structural models, inverse probability of treatment weighting, treatment effect heterogeneity, SAVE trial, hypertension, cardiovascular risk stratification
Open Access status: green
OpenAlex ID: W4387296852
